Faiez Zannad

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1175832/faiez-zannad-publications-by-year.pdf
Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

633 papers	64,961 citations	98 h-index	245 g-index
708 ext. papers	79,807 ext. citations	8.8 avg, IF	7.36 L-index

#	Paper	IF	Citations
633	Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management.. *Heart*, **2022**,	5.1	10
632	A Randomized Controlled Trial of Renin-Angiotensin-Aldosterone System Inhibitor Management in Patients Admitted in Hospital with COVID-19.. *American Heart Journal*, **2022**, 247, 76-76	4.9	2
631	Early Benefit with Empagliflozin in Heart Failure with Preserved Ejection Fraction Insights from the EMPEROR-Preserved Trial.. *European Journal of Heart Failure*, **2022**,	12.3	4
630	Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure.. *Clinical Research in Cardiology*, **2022**, 1	6.1	0
629	Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.. *Journal of the American College of Cardiology*, **2022**, 79, 1129-1137	15.1	1
628	Impact of smoking on cardiovascular risk and premature ageing: Findings from the STANISLAS cohort.. *Atherosclerosis*, **2022**, 346, 1-9	3.1	1
627	Influence of race in the estimation of glomerular filtration rate in patients with a high cardiovascular and renal risk.. *CKJ: Clinical Kidney Journal*, **2022**, 15, 822-824	4.5	0
626	Weak Association Between Genetic Markers of Hyperuricemia and Cardiorenal Outcomes: Insights From the STANISLAS Study Cohort With a 20-Year Follow-Up.. *Journal of the American Heart Association*, **2022**, e023301	6	
625	Differences in biomarkers and molecular pathways according to age for patients with HFrEF. *Cardiovascular Research*, **2021**, 117, 2228-2236	9.9	3
624	Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. *European Heart Journal*, **2021**,	9.5	26
623	Factors Associated With Racial and Ethnic Diversity Among Heart Failure Trial Participants: A Systematic Bibliometric Review.. *Circulation: Heart Failure*, **2021**, CIRCHEARTFAILURE121008685	7.6	5
622	Weight changes in heart failure with preserved ejection fraction: findings from TOPCAT. *Clinical Research in Cardiology*, **2021**, 1	6.1	2
621	Circulating Biomarkers and Cardiac Structure and Function in Rheumatoid Arthritis. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 754784	5.4	0
620	Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. *Lancet Diabetes and Endocrinology,the*, **2021**,	18.1	3
619	Aspirin use is associated with increased risk for incident heart failure: a patient-level pooled analysis. *ESC Heart Failure*, **2021**,	3.7	1
618	Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial. *European Journal of Heart Failure*, **2021**,	12.3	2
617	Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCAT. *European Journal of Heart Failure*, **2021**,	12.3	1

616	Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. *Circulation*, **2021**,	16.7	12
615	No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial. *Archives of Cardiovascular Diseases*, **2021**, 114, 814-817	2.7	1
614	The prevalence and clinical associations of ultrasound measures of congestion in patients at risk of developing heart failure. *European Journal of Heart Failure*, **2021**, 23, 1831-1840	12.3	2
613	Non-fatal cardiovascular events preceding sudden cardiac death in patients with an acute myocardial infarction complicated by heart failure: insights from the high-risk myocardial infarction database. *European Heart Journal: Acute Cardiovascular Care*, **2021**, 10, 127-131	4.3	1
612	Design and Rationale of the National Tunisian Registry of Heart Failure (NATURE-HF): Protocol for a Multicenter Registry Study. *JMIR Research Protocols*, **2021**, 10, e12262	2	0
611	The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ROMicsPin AGEing (HOMAGE) randomized clinical trial. *European Heart Journal*, **2021**, 42, 684-696	9.5	23
610	Ultrasound imaging of congestion in heart failure: examinations beyond the heart. *European Journal of Heart Failure*, **2021**, 23, 703-712	12.3	21
609	Plasma D-dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER-HF trial. *European Journal of Heart Failure*, **2021**, 23, 648-656	12.3	5
608	Red cell distribution width in patients with diabetes and myocardial infarction: An analysis from the EXAMINE trial. *Diabetes, Obesity and Metabolism*, **2021**, 23, 1580-1587	6.7	5
607	Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials. *Circulation*, **2021**, 143, 949-958	16.7	2
606	Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. *Journal of the American College of Cardiology*, **2021**, 77, 1381-1392	15.1	30
605	The value of spot urinary creatinine as a marker of muscle wasting in patients with new-onset or worsening heart failure. *Journal of Cachexia, Sarcopenia and Muscle*, **2021**, 12, 555-567	10.3	3
604	Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. *European Journal of Heart Failure*, **2021**, 23, 983-991	12.3	16
603	A call to action for new global approaches to cardiovascular disease drug solutions. *European Heart Journal*, **2021**, 42, 1464-1475	9.5	16
602	Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire. *European Journal of Heart Failure*, **2021**, 23, 567-577	12.3	3
601	Blood pressure reduction and anti-hypertensive treatment choice: A post-hoc analysis of the SPRINT trial. *Clinical Cardiology*, **2021**, 44, 665-674	3.3	1
600	Data Sharing Under the General Data Protection Regulation: Time to Harmonize Law and Research Ethics?. *Hypertension*, **2021**, 77, 1029-1035	8.5	10
599	The struggle towards a Universal Definition of Heart Failure-how to proceed?. *European Heart Journal*, **2021**, 42, 2331-2343	9.5	19

598	Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. *Circulation: Heart Failure*, **2021**, 14, e007901	7.6	2
597	Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. *European Heart Journal - Cardiovascular Pharmacotherapy*, **2021**,	6.4	1
596	Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. *JACC: Heart Failure* , **2021**, 9, 268-277	7.9	13
595	Soluble Angiotensin-Converting Enzyme 2, Cardiac Biomarkers, Structure, and Function, and Cardiovascular Events (from the Atherosclerosis Risk in Communities Study). *American Journal of Cardiology*, **2021**, 146, 15-21	3	5
594	Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to TAilored Treatment in chronic heart failure. *Clinical Cardiology*, **2021**, 44, 780-788	3.3	1
593	Non-adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatography-tandem mass spectrometry (results of a prospective multicentre study). *European Journal of Heart Failure*, **2021**, 23, 1182-1190	12.3	5
592	Urinary peptides in heart failure: a link to molecular pathophysiology. *European Journal of Heart Failure*, **2021**, 23, 1875-1887	12.3	14
591	Epidemiology of heart failure and long-term follow-up outcomes in a north-African population: Results from the NAtional TUnisian REgistry of Heart Failure (NATURE-HF). *PLoS ONE*, **2021**, 16, e0251658	3.7	1
590	Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. *Journal of Hypertension*, **2021**, 39, 1522-1545	1.9	7
589	Histone deacetylase inhibitors for cardiovascular conditions and healthy longevity. *The Lancet Healthy Longevity*, **2021**, 2, e371-e379	9.5	
588	What can heart failure trialists learn from oncology trialists?. *European Heart Journal*, **2021**, 42, 2373-2383	9.5	4
587	Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial. *Circulation: Heart Failure*, **2021**, 14, e008075	7.6	2
586	Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum. *European Journal of Heart Failure*, **2021**, 23, 1170-1181	12.3	5
585	Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial. *European Journal of Heart Failure*, **2021**, 23, 1477-1484	12.3	1
584	Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. *European Heart Journal*, **2021**, 42, 4442-4451	9.5	6
583	Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial. *European Journal of Heart Failure*, **2021**, 23, 1529-1538	12.3	7
582	Ending Gender Inequality in Cardiovascular Clinical Trial Leadership: JACC Review Topic of the Week. *Journal of the American College of Cardiology*, **2021**, 77, 2960-2972	15.1	14
581	Serum microRNAs and antifibrotic response to eplerenone in acute myocardial infarction complicated by systolic dysfunction. *International Journal of Cardiology*, **2021**, 332, 35-37	3.2	2

580	Identification of sex-specific biomarkers predicting new-onset heart failure. *ESC Heart Failure*, **2021**, 8, 3512-3520	3.7	1
579	A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions. *Circulation*, **2021**, 144, 159-169	16.7	8
578	Heart failure treatment up-titration and outcome and age: an analysis of BIOSTAT-CHF. *European Journal of Heart Failure*, **2021**, 23, 436-444	12.3	6
577	Prevalence, risk factors and proteomic bioprofiles associated with heart failure in rheumatoid arthritis: The RA-HF study. *European Journal of Internal Medicine*, **2021**, 85, 41-49	3.9	3
576	Drug development in oncology and devices-lessons for heart failure drug development and approval? a review. *Heart Failure Reviews*, **2021**, 26, 255-262	5	
575	Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. *Circulation*, **2021**, 143, 326-336	16.7	74
574	Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced. *Circulation*, **2021**, 143, 310-321	16.7	55
573	Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial. *Journal of Cardiac Failure*, **2021**, 27, 233-241	3.3	4
572	Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (TRS-HF) in patients in the ACCORD trial. *Diabetes, Obesity and Metabolism*, **2021**, 23, 782-790	6.7	3
571	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. *New England Journal of Medicine*, **2021**, 384, 105-116	59.2	164
570	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. *Circulation*, **2021**, 143, 337-349	16.7	80
569	The Future of Meat: Health Impact Assessment with Randomized Evidence. *American Journal of Medicine*, **2021**, 134, 569-575	2.4	2
568	Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF. *European Journal of Heart Failure*, **2021**, 23, 43-57	12.3	5
567	The Decline of the Experimental Paradigm During the COVID-19 Pandemic: A Template for the Future. *American Journal of Medicine*, **2021**, 134, 166-175	2.4	7
566	Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure. *Journal of Cardiac Failure*, **2021**, 27, 297-308	3.3	2
565	Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. *European Heart Journal*, **2021**, 42, 152-161	9.5	82
564	Bias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches. *Heart Failure Reviews*, **2021**, 26, 11-21	5	1
563	Development, validation, and implementation of biomarker testing in cardiovascular medicine state-of-the-art: proceedings of the European Society of Cardiology-Cardiovascular Round Table. *Cardiovascular Research*, **2021**, 117, 1248-1256	9.9	1

562	Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. *European Heart Journal*, **2021**, 42, 671-680	9.5	36
561	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. *European Heart Journal*, **2021**, 42, 1203-1212	9.5	34
560	Why are mineralocorticoid receptor antagonists the Cinderella in evidence-based treatment of myocardial infarction complicated with heart failure? Lessons from PARADISE-MI. *European Heart Journal*, **2021**,	9.5	3
559	Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. *European Heart Journal*, **2021**,	9.5	3
558	Impact of Anti-hypertensive Therapy in the Sexual Health of Men and Women: An Analysis From the SPRINT Trial. *American Journal of Hypertension*, **2021**, 34, 760-772	2.3	0
557	Circulating multimarker approach to identify patients with preclinical left ventricular remodelling and/or diastolic dysfunction. *ESC Heart Failure*, **2021**, 8, 1700-1705	3.7	5
556	Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. *Hypertension*, **2021**, 77, 546-556	8.5	7
555	Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. *European Journal of Heart Failure*, **2021**, 23, 776-784	12.3	3
554	Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. *Journal of the American Heart Association*, **2021**, 10, e020053	6	6
553	Risk stratification with echocardiographic biomarkers in heart failure with preserved ejection fraction: the media echo score. *ESC Heart Failure*, **2021**, 8, 1827-1839	3.7	7
552	Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial. *Cardiovascular Diabetology*, **2021**, 20, 163	8.7	2
551	Heart Failure and a Preserved Ejection Fraction: A Side-by-Side Examination of the PARAGON-HF and EMPEROR-Preserved Trials. *Circulation*, **2021**, 144, 1193-1195	16.7	11
550	Effect of patient-centered transitional care services on patient-reported outcomes in heart failure: sex-specific analysis of the PACT-HF randomized controlled trial. *European Journal of Heart Failure*, **2021**, 23, 1488-1498	12.3	7
549	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. *Circulation*, **2021**, 144, 1284-1294	16.7	30
548	Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT-CHF. *European Journal of Heart Failure*, **2021**, 23, 1750-1758	12.3	8
547	Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. *Journal of Cardiac Failure*, **2021**, 27, 888-895	3.3	4
546	Empagliflozin and Major Renal Outcomes in Heart Failure. *New England Journal of Medicine*, **2021**, 385, 1531-1533	59.2	19
545	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. *New England Journal of Medicine*, **2021**, 385, 1451-1461	59.2	358

544	Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. *European Heart Journal*, **2021**, 42, 4455-4464	9.5	5
543	Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial. *European Journal of Heart Failure*, **2021**, 23, 1798-1799	12.3	4
542	Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES. *European Journal of Heart Failure*, **2021**,	12.3	2
541	Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction. *Journal of the American Heart Association*, **2021**, 10, e022069	6	4
540	Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. *Journal of the American College of Cardiology*, **2021**, 78, 1321-1332	15.1	10
539	Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. *Journal of the American College of Cardiology*, **2021**, 78, 1337-1348	15.1	8
538	Isolated diastolic hypertension and target organ damage: Findings from the STANISLAS cohort. *Clinical Cardiology*, **2021**, 44, 1516-1525	3.3	1
537	Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials. *American Heart Journal*, **2021**, 240, 73-80	4.9	0
536	Patient partnership in cardiovascular clinical trials.. *European Heart Journal*, **2021**,	9.5	1
535	Kidney function assessment and endpoint ascertainment in clinical trials.. *European Heart Journal*, **2021**,	9.5	6
534	Reduced Diuretic Dose in Patients Treated With Eplerenone: Data From the EPHESUS Trial. *Circulation: Heart Failure*, **2020**, 13, e006597	7.6	8
533	Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. *American Journal of Hypertension*, **2020**, 33, 1092-1101	2.3	9
532	Plasma Galectin-3 predicts deleterious vascular dysfunction affecting post-myocardial infarction patients: An explanatory study. *PLoS ONE*, **2020**, 15, e0232572	3.7	2
531	Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. *Nature Reviews Cardiology*, **2020**, 17, 641-655	14.8	41
530	Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT. *European Journal of Heart Failure*, **2020**, 22, 1615-1624	12.3	9
529	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). *European Heart Journal*, **2020**, 41, 2109-2117	9.5	42
528	Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop. *American Journal of Kidney Diseases*, **2020**, 76, 109-120	7.4	4
527	Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*, **2020**, 75, 2836-2850	15.1	36

526	Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. *Journal of the American College of Cardiology*, **2020**, 75, 1644-1656	15.1	23
525	Association of Dietary Patterns Derived Using Reduced-Rank Regression With Subclinical Cardiovascular Damage According to Generation and Sex in the STANISLAS Cohort. *Journal of the American Heart Association*, **2020**, 9, e013836	6	6
524	PCSK9 Protein and rs562556 Polymorphism Are Associated With Arterial Plaques in Healthy Middle-Aged Population: The STANISLAS Cohort. *Journal of the American Heart Association*, **2020**, 9, e014758	6	9
523	Covariate adjusted reanalysis of the I-Preserve trial. *Clinical Research in Cardiology*, **2020**, 109, 1358-1365	6.1	5
522	Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure. *ESC Heart Failure*, **2020**, 7, 953-963	3.7	3
521	Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction. *Journal of the American College of Cardiology*, **2020**, 76, 1-13	15.1	41
520	Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries. *European Journal of Heart Failure*, **2020**, 22, 1472-1482	12.3	14
519	Myocardial reperfusion reverses the J-curve association of cardiovascular risk and diastolic blood pressure in patients with left ventricular dysfunction and heart failure after myocardial infarction: insights from the EPHESUS trial. *European Heart Journal*, **2020**, 41, 1673-1683	9.5	17
518	Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals. *Nephrology Dialysis Transplantation*, **2020** , 35, 1761-1769	4.3	1
517	Enhanced clinical phenotyping by mechanistic bioprofiling in heart failure with preserved ejection fraction: insights from the MEDIA-DHF study (The Metabolic Road to Diastolic Heart Failure). *Biomarkers*, **2020**, 25, 201-211	2.6	11
516	Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. *European Journal of Heart Failure*, **2020**, 22, 834-844	12.3	13
515	Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. *European Journal of Heart Failure*, **2020**, 22, 848-855	12.3	9
514	Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. *European Journal of Heart Failure*, **2020**, 22, 1711-1723	12.3	22
513	Biomarkers in patients with heart failure and central sleep apnoea: findings from the SERVE-HF trial. *ESC Heart Failure*, **2020**, 7, 503-511	3.7	6
512	Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study. *Clinical Research in Cardiology*, **2020**, 109, 967-977	6.1	3
511	Correlation of laboratory haemoconcentration measures with filling pressures obtained via pulmonary arterial pressure sensors in ambulatory heart failure patients. *European Journal of Heart Failure*, **2020**, 22, 1907-1911	12.3	4
510	Daily home monitoring of potassium, creatinine, and estimated plasma volume in heart failure post-discharge. *ESC Heart Failure*, **2020**, 7, 1257-1263	3.7	7
509	Improved cardiac and venous pressures during hospital stay in patients with acute heart failure: an echocardiography and biomarkers study. *ESC Heart Failure*, **2020**, 7, 996-1006	3.7	5

508	A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure. *European Journal of Heart Failure*, **2020**, 22, 821-833	12.3	11
507	Eplerenone prevents an increase in serum carboxy-terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure. *European Journal of Heart Failure*, **2020**, 22, 901-903	12.3	5
506	Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. *American Journal of Cardiology*, **2020**, 125, 1577-1581	3	1
505	Impact of Uric Acid on Hypertension Occurrence and Target Organ Damage: Insights From the STANISLAS Cohort With a 20-Year Follow-up. *American Journal of Hypertension*, **2020**, 33, 869-878	2.3	8
504	Diagnostic performance of congestion score index evaluated from chest radiography for acute heart failure in the emergency department: A retrospective analysis from the PARADISE cohort. *PLoS Medicine*, **2020**, 17, e1003419	11.6	4
503	Circulating plasma proteins and new-onset diabetes in a population-based study: proteomic and genomic insights from the STANISLAS cohort. *European Journal of Endocrinology*, **2020**, 183, 285-295	6.5	3
502	Reproducibility in Echotracking Assessment of Local Carotid Stiffness, Diameter and Thickness in a Population-based Study (The STANISLAS Cohort Study). *Artery Research*, **2020**, 26, 5	2.2	3
501	Use of the Win Ratio in Cardiovascular Trials. *JACC: Heart Failure*, **2020**, 8, 441-450	7.9	13
500	Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. *Lancet, The*, **2020**, 396, 121-128	40	133
499	Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets. *European Journal of Heart Failure*, **2020**, 22, 70-80	12.3	14
498	Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF. *European Journal of Internal Medicine*, **2020**, 71, 62-69	3.9	6
497	Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. *European Journal of Heart Failure*, **2020**, 22, 1147-1155	12.3	22
496	Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. *Nature Communications*, **2020**, 11, 163	17.4	140
495	Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. *Journal of the American Heart Association*, **2020**, 9, e012797	6	12
494	Body fat phenotypes and treatment response to spironolactone in ambulatory patients with heart failure and preserved ejection fraction: a post-hoc analysis of the Aldo-DHF trial. *European Journal of Heart Failure*, **2020**, 22, 559-561	12.3	
493	Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction. *European Journal of Heart Failure*, **2020**, 22, 1402-1411	12.3	10
492	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. *Circulation*, **2020**, 141, 338-351	16.7	122
491	Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial. *European Journal of Heart Failure*, **2020**, 22, 164-167	12.3	2

490	Medical Therapies for Heart Failure With Preserved Ejection Fraction. *Hypertension*, **2020**, 75, 23-32	8.5	25
489	Cardiovascular and non-cardiovascular death distinction: the utility of troponin beyond N-terminal pro-B-type natriuretic peptide. Findings from the BIOSTAT-CHF study. *European Journal of Heart Failure*, **2020**, 22, 81-89	12.3	10
488	Estimating the Lifetime Benefits of Treatments for Heart Failure. *JACC: Heart Failure*, **2020**, 8, 984-995	7.9	2
487	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. *European Journal of Heart Failure*, **2020**, 22, 2160-2171	12.3	24
486	Improving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*, **2020**, 76, 435-450	15.1	5
485	Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. *European Journal of Heart Failure*, **2020**, 22, 2393-2398	12.3	9
484	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. *European Journal of Heart Failure*, **2020**, 22, 2383-2392	12.3	41
483	Improved cardiovascular risk prediction in patients with end-stage renal disease on hemodialysis using machine learning modeling and circulating microribonucleic acids. *Theranostics*, **2020**, 10, 8665-8676	12.1	8
482	Acute myocardial infarction and acute heart failure in the Middle East and North Africa: Study design and pilot phase study results from the PEACE MENA registry. *PLoS ONE*, **2020**, 15, e0236292	3.7	3
481	Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. *Journal of the American College of Cardiology*, **2020**, 76, 503-514	15.1	27
480	Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus. *American Heart Journal*, **2020**, 229, 40-51	4.9	4
479	Ten lessons from the EMPEROR-Reduced trial. *European Journal of Heart Failure*, **2020**, 22, 1991-1993	12.3	1
478	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. *New England Journal of Medicine*, **2020**, 383, 1413-1424	59.2	1099
477	SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. *Lancet, The*, **2020**, 396, 819-829	40	355
476	Totality of evidence in trials of sodium-glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice. *European Heart Journal*, **2020**, 41, 3398-3401	9.5	14
475	Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. *Circulation*, **2020**, 142, 1236-1245	16.7	32
474	Serum potassium in the PARADIGM-HF trial. *European Journal of Heart Failure*, **2020**, 22, 2056-2064	12.3	14
473	Arteriovenous fistula thrombosis is associated with increased all-cause and cardiovascular mortality in haemodialysis patients from the AURORA trial. *CKJ: Clinical Kidney Journal*, **2020**, 13, 116-122	4.5	6

472	Chest X-ray quantification of admission lung congestion as a prognostic factor in patients admitted for worsening heart failure from the ICALOR cohort study. *International Journal of Cardiology*, **2020**, 299, 192-198	3.2	8
471	Plasma Galectin-3 predicts deleterious vascular dysfunction affecting post-myocardial infarction patients: An explanatory study **2020**, 15, e0232572		
470	Plasma Galectin-3 predicts deleterious vascular dysfunction affecting post-myocardial infarction patients: An explanatory study **2020**, 15, e0232572		
469	Plasma Galectin-3 predicts deleterious vascular dysfunction affecting post-myocardial infarction patients: An explanatory study **2020**, 15, e0232572		
468	Plasma Galectin-3 predicts deleterious vascular dysfunction affecting post-myocardial infarction patients: An explanatory study **2020**, 15, e0232572		
467	Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non-sudden cardiac death in myocardial infarction survivors with heart failure. *European Journal of Heart Failure*, **2019**, 21, 1248-1258	12.3	15
466	Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. *Lancet, The*, **2019**, 394, 1254-1263	40	83
465	Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. *New England Journal of Medicine*, **2019**, 381, 1609-1620	59.2	705
464	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. *Lancet, The*, **2019**, 393, 407-415	40	300
463	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. *European Journal of Heart Failure*, **2019**, 21, 272-285	12.3	99
462	A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. *European Heart Journal*, **2019**, 40, 3593-3602	9.5	38
461	Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure. *Circulation: Heart Failure*, **2019**, 12, e005875	7.6	30
460	Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. *Circulation: Heart Failure*, **2019**, 12, e005897	7.6	33
459	Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction. *American Heart Journal*, **2019** , 215, 83-90	4.9	0
458	Estimated Long-Term Survival With Eplerenone. *Journal of the American College of Cardiology*, **2019** , 73, 2357-2359	15.1	5
457	The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. *European Journal of Heart Failure*, **2019**, 21, 965-973	12.3	81
456	Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. *JAMA Cardiology*, **2019**, 4, 515-523	16.2	34
455	The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward. *Kidney International*, **2019**, 95, 747-749	9.9	14

454	Heart failure drug treatment. *Lancet, The*, **2019**, 393, 1034-1044	40	135
453	The continuous heart failure spectrum: moving beyond an ejection fraction classification. *European Heart Journal*, **2019**, 40, 2155-2163	9.5	107
452	Nondipping Pattern and Cardiovascular and Renal Damage in a Population-Based Study (The STANISLAS Cohort Study). *American Journal of Hypertension*, **2019**, 32, 620-628	2.3	12
451	Mid-term prognostic impact of residual pulmonary congestion assessed by radiographic scoring in patients admitted for worsening heart failure. *International Journal of Cardiology*, **2019**, 289, 91-98	3.2	13
450	Income Inequality and Outcomes in Heart Failure: A Global Between-Country Analysis. *JACC: Heart Failure*, **2019**, 7, 336-346	7.9	42
449	Endothelial-driven increase in plasma thrombin generation characterising a new hypercoagulable phenotype in acute heart failure. *International Journal of Cardiology*, **2019**, 274, 195-201	3.2	14
448	Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure. *Heart*, **2019**, 105, 307-314	5.1	18
447	Heart failure around the world. *European Journal of Heart Failure*, **2019**, 21, 1187-1196	12.3	31
446	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. *European Journal of Heart Failure*, **2019**, 21, 1270-1278	12.3	73
445	Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. *JACC: Heart Failure*, **2019**, 7, 862-874	7.9	40
444	Arterial Remodeling and Dysfunction in the ZSF1 Rat Model of Heart Failure With Preserved Ejection Fraction. *Circulation: Heart Failure*, **2019**, 12, e005596	7.6	13
443	Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. *European Journal of Heart Failure*, **2019**, 21, 1279-1287	12.3	133
442	Eplerenone in patients with myocardial infarction and "mid-range" ejection fraction: An analysis from the EPHESUS trial. *Clinical Cardiology*, **2019**, 42, 1106-1112	3.3	9
441	Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes. *JACC Basic To Translational Science*, **2019**, 4, 831-840	8.7	42
440	Telomere length tracking in children and their parents: implications for adult onset diseases. *FASEB Journal*, **2019**, 33, 14248-14253	0.9	20
439	Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. *European Journal of Heart Failure*, **2019**, 21, 386-388	12.3	21
438	Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial. *European Journal of Heart Failure*, **2019**, 21, 345-351	12.3	28
437	Income level and inequality as complement to geographical differences in cardiovascular trials. *American Heart Journal*, **2019**, 218, 66-74	4.9	12

436	MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPHASIS-HF, and TOPCAT. *JACC: Heart Failure*, **2019**, 7, 1012-1021	7.9	14
435	Heritability of a resting heart rate in a 20-year follow-up family cohort with GWAS data: Insights from the STANISLAS cohort. *European Journal of Preventive Cardiology*, **2019**, 2047487319890763	3.9	3
434	Health-related determinants of undiagnosed arterial hypertension: a population-based study. *Family Practice*, **2019**, 36, 276-283	1.9	5
433	Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. *European Heart Journal*, **2019**, 40, 2907-2919	9.5	22
432	Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study. *European Journal of Heart Failure*, **2019**, 21, 218-226	12.3	13
431	Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). *American Journal of Cardiology*, **2019**, 123, 382-391	3	7
430	Echocardiographic diastolic function evolution in patients with an anterior Q-wave myocardial infarction: insights from the REVE-2 study. *ESC Heart Failure*, **2019**, 6, 70-79	3.7	2
429	Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-CHF. *European Journal of Heart Failure*, **2019**, 21, 877-886	12.3	34
428	Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study. *European Journal of Heart Failure*, **2019**, 21, 112-120	12.3	24
427	EditorB Choice- Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction. *European Heart Journal: Acute Cardiovascular Care*, **2019**, 8, 231-241	4.3	16
426	Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints. *European Heart Journal*, **2019**, 40, 880-886	9.5	23
425	World Heart Federation Roadmap for Heart Failure. *Global Heart*, **2019**, 14, 197-214	2.9	33
424	The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions. *European Journal of Heart Failure*, **2018**, 20, 963-972	12.3	27
423	Cohort Profile: Rationale and design of the fourth visit of the STANISLAS cohort: a familial longitudinal population-based cohort from the Nancy region of France. *International Journal of Epidemiology*, **2018**, 47, 395-395j	7.8	21
422	Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome. *Clinical Cardiology*, **2018**, 41, 1022-1027	3.3	3
421	Impact of the interruption of a large heart failure regional disease management programme on hospital admission rates: a population-based study. *European Journal of Heart Failure*, **2018**, 20, 1066-1068	12.3	5
420	Relation of High Serum Bilirubin to Short-Term Mortality Following a Myocardial Infarction Complicated by Left Ventricular Systolic Dysfunction (from the High-Risk Myocardial Infarction Database Initiative). *American Journal of Cardiology*, **2018**, 121, 1015-1020	3	10
419	Evolution of natriuretic peptide biomarkers in heart failure: Implications for clinical care and clinical trials. *International Journal of Cardiology*, **2018**, 254, 215-221	3.2	17

418	Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. *Clinical Journal of the American Society of Nephrology: CJASN*, **2018**, 13, 398-405	6.9	18
417	Interpretation of the ATHENA Trial-Caveats and Future Directions. *JAMA Cardiology*, **2018**, 3, 89-90	16.2	1
416	Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. *Journal of the American College of Cardiology*, **2018**, 71, 727-735	15.1	18
415	Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF. *Journal of the American College of Cardiology*, **2018**, 71, 386-398	15.1	22
414	Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion. *European Journal of Heart Failure*, **2018**, 20, 738-747	12.3	76
413	Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF. *European Journal of Heart Failure*, **2018**, 20, 923-930	12.3	41
412	Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. *International Journal of Cardiology*, **2018**, 253, 84-90	3.2	32
411	Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction. *American Journal of Hypertension*, **2018**, 31, 407-414	2.3	20
410	Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarction Database Initiative. *European Journal of Heart Failure*, **2018**, 20, 323-331	12.3	11
409	Teasing Apart Heart Failure With Preserved Ejection Fraction Phenotypes With Echocardiographic Imaging: Potential Approach to Research and Clinical Practice. *Circulation Research*, **2018**, 122, 23-25	15.7	9
408	Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action. *European Heart Journal*, **2018**, 39, 2793-2799	9.5	19
407	High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial. *Diabetes, Obesity and Metabolism*, **2018**, 20, 654-659	6.7	19
406	Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality. *Circulation*, **2018**, 137, 1320-1330	16.7	76
405	Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. *European Journal of Heart Failure*, **2018**, 20, 281-291	12.3	17
404	Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. *ESC Heart Failure*, **2018**, 5, 139-148	3.7	14
403	Mineralocorticoid receptor antagonists in patients with acute myocardial infarction - A systematic review and meta-analysis of randomized trials. *American Heart Journal*, **2018**, 195, 60-69	4.9	14
402	Predictors of atherosclerotic events in patients on haemodialysis: post hoc analyses from the AURORA study. *Nephrology Dialysis Transplantation*, **2018**, 33, 102-112	4.3	11
401	Relationship between left ventricular ejection fraction and mortality after myocardial infarction complicated by heart failure or left ventricular dysfunction. *International Journal of Cardiology*, **2018**, 272, 260-266	3.2	13

400	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. *Circulation: Heart Failure*, **2018**, 11, e004962	7.6	70
399	Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns. *Circulation: Heart Failure*, **2018**, 11, e004926	7.6	13
398	Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). *American Journal of Cardiology*, **2018**, 122, 255-260	3	4
397	Reply: Carbohydrate Antigen-125 in Heart Failure: An Overlooked Biomarker of Congestion. *JACC: Heart Failure*, **2018**, 6, 442-443	7.9	1
396	First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF. *American Heart Journal*, **2018**, 204, 139-150	4.9	17
395	Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. *Journal of the American College of Cardiology*, **2018**, 72, 1081-1090	15.1	108
394	Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. *New England Journal of Medicine*, **2018**, 379, 1332-1342	59.2	181
393	Cardiorenal Syndrome Revisited. *Circulation*, **2018**, 138, 929-944	16.7	112
392	Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus. *JACC: Heart Failure*, **2018**, 6, 813-822	7.9	20
391	Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. *European Heart Journal*, **2018**, 39, 3867-3875	9.5	33
390	Association between abdominal adiposity and 20-year subsequent aortic stiffness in an initially healthy population-based cohort. *Journal of Hypertension*, **2018**, 36, 2077-2084	1.9	4
389	Cardiovascular Outcomes Reported in Hemodialysis Trials. *Journal of the American College of Cardiology*, **2018**, 71, 2802-2810	15.1	14
388	Rising incidence of heart failure demands action. *Lancet, The*, **2018**, 391, 518-519	40	35
387	Integrative Assessment of Congestion in Heart Failure Throughout the Patient Journey. *JACC: Heart Failure*, **2018**, 6, 273-285	7.9	78
386	Nuclear magnetic resonance-based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation: results from PROSPER and FINRISK 1997. *European Journal of Heart Failure*, **2018**, 20, 663-673	12.3	29
385	Adaptive servo-ventilation for central sleep apnoea in systolic heart failure: results of the major substudy of SERVE-HF. *European Journal of Heart Failure*, **2018**, 20, 536-544	12.3	40
384	Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial. *European Journal of Heart Failure*, **2018**, 20, 677-686	12.3	13
383	Hyponatraemia, hyperglycaemia and worsening renal function at first blood sample on emergency department admission as predictors of in-hospital death in patients with dyspnoea with suspected acute heart failure: retrospective observational analysis of the PARADISE cohort. *BMJ Open*, **2018**, 8, e019557	3	9

382	Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial. *European Journal of Heart Failure*, **2018**, 20, 1760-1763	12.3	2
381	Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. *Circulation: Cardiovascular Quality and Outcomes*, **2018**, 11, e004783	5.8	7
380	Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial. *Journal of the American Heart Association*, **2018**, 7, e009114	6	13
379	Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. *Circulation*, **2018**, 138, 1039-1053	16.7	13
378	Heart rate, pulse pressure and mortality in patients with myocardial infarction complicated by heart failure. *International Journal of Cardiology*, **2018**, 271, 181-185	3.2	6
377	Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. *International Journal of Cardiology*, **2018**, 271, 132-139	3.2	74
376	Mineralocorticoid Receptor Antagonists in ST-Segment Elevation Myocardial Infarction. *JAMA Internal Medicine*, **2018**, 178, 920-921	11.5	1
375	Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients. *Intensive Care Medicine*, **2018**, 44, 847-856	14.5	71
374	Waist-to-hip ratio and mortality in heart failure. *European Journal of Heart Failure*, **2018**, 20, 1269-1277	12.3	56
373	The future of pleiotropic therapy in heart failure. Lessons from the benefits of exercise training on endothelial function. *European Journal of Heart Failure*, **2017**, 19, 603-614	12.3	23
372	Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial. *Diabetes, Obesity and Metabolism*, **2017**, 19, 664-671	6.7	41
371	Twenty-Four-Hour Blood Pressure Monitoring to Predict and Assess Impact of Renal Denervation: The DENERHTN Study (Renal Denervation for Hypertension). *Hypertension*, **2017**, 69, 494-500	8.5	19
370	Burden of musculoskeletal disorders in the Eastern Mediterranean Region, 1990-2013: findings from the Global Burden of Disease Study 2013. *Annals of the Rheumatic Diseases*, **2017**, 76, 1365-1373	2.4	56
369	Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care). *Circulation*, **2017**, 135, 1911-1921	16.7	43
368	Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. *European Journal of Heart Failure*, **2017**, 19, 627-634	12.3	110
367	The burden of proof: The current state of atrial fibrillation prevention and treatment trials. *Heart Rhythm*, **2017**, 14, 763-782	6.7	23
366	Serum Chloride and Sodium Interplay in Patients With Acute Myocardial Infarction and Heart Failure With Reduced Ejection Fraction: An Analysis From the High-Risk Myocardial Infarction Database Initiative. *Circulation: Heart Failure*, **2017**, 10,	7.6	28
365	Myocardial fibrosis: biomedical research from bench to bedside. *European Journal of Heart Failure*, **2017**, 19, 177-191	12.3	195

364	Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial. *Diabetes, Obesity and Metabolism*, **2017**, 19, 962-969	6.7	19
363	Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?. *European Journal of Heart Failure*, **2017**, 19, 974-986	12.3	23
362	A history of diabetes predicts outcomes following myocardial infarction: an analysis of the 28 771 patients in the High-Risk MI Database. *European Journal of Heart Failure*, **2017**, 19, 635-642	12.3	20
361	Cardiovascular Outcome Trials in Patients With Advanced Kidney Disease: Time for Action. *Circulation*, **2017**, 135, 1769-1771	16.7	26
360	Risk for Incident Heart Failure: A Subject-Level Meta-Analysis From the Heart "OMics" in AGEing (HOMAGE) Study. *Journal of the American Heart Association*, **2017**, 6,	6	27
359	Reproducibility of echocardiographic assessment of 2D-derived longitudinal strain parameters in a population-based study (the STANISLAS Cohort study). *International Journal of Cardiovascular Imaging*, **2017**, 33, 1361-1369	2.5	17
358	Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. *European Journal of Heart Failure*, **2017**, 19, 552-562	12.3	19
357	Prognostic factors associated with 15-year mortality in patients with hospitalized systolic HF: Results of the observational community-based EPICAL cohort study. *International Journal of Cardiology*, **2017**, 228, 940-947	3.2	4
356	Impact of Changes in Consensus Diagnostic Recommendations on the Echocardiographic Prevalence of Diastolic Dysfunction. *Journal of the American College of Cardiology*, **2017**, 69, 3119-3121	15.1	41
355	Redefining the role of biomarkers in heart failure trials: expert consensus document. *Heart Failure Reviews*, **2017**, 22, 263-277	5	13
354	Lack of Diuretic Efficiency (but Not Low Diuresis) Early in An Acutely Decompensated Heart Failure Episode Is Associated with Increased 180-Day Mortality. *CardioRenal Medicine*, **2017**, 7, 137-149	2.8	8
353	New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. *European Journal of Heart Failure*, **2017**, 19, 718-727	12.3	15
352	Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. *European Journal of Heart Failure*, **2017**, 19, 1186-1197	12.3	55
351	Heart rate prediction of outcome in heart failure following myocardial infarction depend on heart rhythm status an analysis from the high-risk myocardial infarction database initiative. *International Journal of Cardiology*, **2017**, 249, 274-281	3.2	1
350	Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study. *JACC: Heart Failure*, **2017**, 5, 724-734	7.9	49
349	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. *European Journal of Heart Failure*, **2017**, 19, 1361-1378	12.3	73
348	The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis. *Journal of the American College of Cardiology*, **2017**, 70, 2128-2136	15.1	24
347	The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. *European Journal of Heart Failure*, **2017**, 19, 1390-1400	12.3	111

346	Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action. *JAMA Cardiology*, **2017**, 2, 1025-1029	16.2	217
345	Role of Payers in the Development of Cardiovascular Therapeutics: Misalignment Between Approval and Reimbursement. *Journal of the American College of Cardiology*, **2017**, 70, 2822-2830	15.1	4
344	Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. *JACC: Heart Failure*, **2017**, 5, 471-482	7.9	176
343	Declining Risk of Sudden Death in Heart Failure. *New England Journal of Medicine*, **2017**, 377, 41-51	59.2	232
342	Long-term vagal stimulation for heart failure: Eighteen month results from the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) trial. *International Journal of Cardiology*, **2017**, 244, 229-234	3.2	54
341	Effect of Significant Weight Change on Inappropriate Implantable Cardioverter-Defibrillator Therapy. *PACE - Pacing and Clinical Electrophysiology*, **2017**, 40, 9-16	1.6	4
340	Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. *European Journal of Heart Failure*, **2017**, 19, 792-799	12.3	28
339	Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative. *European Journal of Heart Failure*, **2017**, 19, 271-279	12.3	22
338	Oxidized LDL, statin use, morbidity, and mortality in patients receiving maintenance hemodialysis. *Free Radical Research*, **2017**, 51, 14-23	4	5
337	Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF. *European Journal of Heart Failure*, **2017**, 19, 1284-1293	12.3	46
336	Health in times of uncertainty in the eastern Mediterranean region, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *The Lancet Global Health*, **2016**, 4, e704-13	13.6	117
335	Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. *Hypertension*, **2016**, 68, 606-13	8.5	18
334	Mechanisms underlying increased mortality risk in patients with heart failure and reduced ejection fraction randomly assigned to adaptive servoventilation in the SERVE-HF study: results of a secondary multistate modelling analysis. *Lancet Respiratory Medicine,the*, **2016**, 4, 873-881	35.1	59
333	A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. *European Heart Journal*, **2016**, 37, 2105-14	9.5	184
332	Roadmap for cardiovascular prevention trials in chronic kidney disease. *Lancet, The*, **2016**, 388, 1964-1966	60	8
331	Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next Steps. *JACC: Heart Failure*, **2016**, 4, 419-27	7.9	34
330	Intima-Media Thickness Is Linearly and Continuously Associated With Systolic Blood Pressure in a Population-Based Cohort (STANISLAS Cohort Study). *Journal of the American Heart Association*, **2016**, 5,	6	44
329	Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges. *European Heart Journal*, **2016**, 37, 2455-64	9.5	27

328	Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. *European Stroke Journal*, **2016**, 1, 93-100	5.6	
327	Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. *Diabetes Care*, **2016**, 39, 1267-73	14.6	38
326	Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study. *European Journal of Heart Failure*, **2016**, 18, 1175-81	12.3	11
325	Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. *American Journal of Cardiology*, **2016**, 117, 1144-50	3	16
324	Heart failure event definitions in drug trials in patients with type 2 diabetes. *Lancet Diabetes and Endocrinology,the*, **2016**, 4, 294-6	18.1	21
323	Left-to-right atrial shunting: new hope for heart failure?. *Lancet, The*, **2016**, 387, 1253-5	40	4
322	Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial). *American Journal of Cardiology*, **2016**, 117, 611-616	3	11
321	Prediction of Left Ventricular Remodeling after a Myocardial Infarction: Role of Myocardial Deformation: A Systematic Review and Meta-Analysis. *PLoS ONE*, **2016**, 11, e0168349	3.7	32
320	Association of Empirically Derived Dietary Patterns with Cardiovascular Risk Factors: A Comparison of PCA and RRR Methods. *PLoS ONE*, **2016**, 11, e0161298	3.7	18
319	Natriuretic Peptides, 6-Min Walk Test, and´Quality-of-Life Questionnaires as Clinically Meaningful Endpoints in HF Trials. *Journal of the American College of Cardiology*, **2016**, 68, 2690-2707	15.1	43
318	Effects of mineralocorticoid receptor antagonists on the risk of thrombosis, bleeding and mortality: A systematic review and meta-analysis of randomized controlled trials. *Thrombosis Research*, **2016**, 144, 32-9	8.2	3
317	New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. *International Journal of Cardiology*, **2016**, 216, 46-51	3.2	19
316	Lung ultrasound: a diagnostic and prognostic tool at every step in the pathway of care for acute heart failure. *American Journal of Emergency Medicine*, **2016**, 34, 656-7	2.9	5
315	Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial. *Journal of the American College of Cardiology*, **2016**, 67, 1917-27	15.1	58
314	Echocardiography in Hypertension in the Era of Risk Stratification and Personalized Medicine. *American Journal of Hypertension*, **2016**, 29, 792-5	2.3	3
313	Adherence to Antihypertensive Treatment and the Blood Pressure-Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial. *Circulation*, **2016**, 134, 847-57	16.7	98
312	Hyperkalemia in Heart Failure. *Journal of the American College of Cardiology*, **2016**, 68, 1575-89	15.1	60
311	Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future. *Pharmacological Research*, **2016**, 113, 585-591	10.2	72

310	A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. *European Journal of Heart Failure*, **2016**, 18, 1411-1414	12.3	22
309	Prognostic Value of the Thrombolysis in Myocardial Infarction Risk Score in ST-Elevation Myocardial Infarction Patients With Left Ventricular Dysfunction (from the EPHESUS Trial). *American Journal of Cardiology*, **2016**, 118, 1442-1447	3	7
308	Evaluation of the Incremental Prognostic Utility of Increasingly Complex Testing in Chronic Heart Failure. *Circulation: Heart Failure*, **2015**, 8, 709-16	7.6	7
307	Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. *American Journal of Cardiology*, **2015**, 116, 1304-10	3	3
306	Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. *Hypertension*, **2015**, 66, 767-75	8.5	99
305	Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction. *European Journal of Heart Failure*, **2015**, 17, 135-43	12.3	15
304	Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. *European Heart Journal*, **2015**, 36, 2310-7	9.5	20
303	Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. *European Journal of Heart Failure*,	12.3	62
302	Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial. *European Journal of Heart Failure*, **2015**,	12.3	56
301	Patient selection in heart failure with preserved ejection fraction clinical trials. *Journal of the American College of Cardiology*, **2015**, 65, 1668-1682	15.1	89
300	Interleukin-33/ST2 system attenuates aldosterone-induced adipogenesis and inflammation. *Molecular and Cellular Endocrinology*, **2015**, 411, 20-7	4.4	18
299	Early and late effects of high- versus low-dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure. *JACC: Heart Failure*, **2015**, 3, 214-23	7.9	14
298	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. *Lancet, The*, **2015**, 385, 2067-76	40	551
297	Atherosclerosis: Recent trials, new targets and future directions. *International Journal of Cardiology* , **2015**, 192, 72-81	3.2	25
296	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). *Europace*, **2015**, 17, 1601-87	3.9	426
295	Prognostic Value of Estimated Plasma Volume in Heart Failure. *JACC: Heart Failure*, **2015**, 3, 886-93	7.9	66
294	To the Editor--Diabetes and sudden death: Let's assess the absolute risk increase rather than the proportional risk from sudden cardiac death!. *Heart Rhythm*, **2015**, 12, e138	6.7	2
293	Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. *New England Journal of Medicine*, **2015**, 373, 1095-105	59.2	649

292	EXAMINE: targeting risk and treatment in diabetes - AuthorsPreply. *Lancet, The*, **2015**, 386, 1445	40	1
291	Long Term Safety and Efficacy Results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) Trial. *Journal of Cardiac Failure*, **2015**, 21, 936	3.3	2
290	The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. *JACC: Heart Failure*, **2015**, 3, 59-67	7.9	127
289	Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. *European Heart Journal*, **2015**, 36, 425-33	9.5	208
288	Global variation in clinical profile, management, and post-discharge outcomes among patients hospitalized for worsening chronic heart failure: findings from the ASTRONAUT trial. *European Journal of Heart Failure*, **2015**, 17, 591-600	12.3	52
287	Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. *European Journal of Heart Failure*, **2015**, 17, 1050-6	12.3	98
286	Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF). *European Journal of Heart Failure*, **2015**, 17, 707-16	12.3	15
285	Prognostic value of residual pulmonary congestion at discharge assessed by lung ultrasound imaging in heart failure. *European Journal of Heart Failure*, **2015**, 17, 1172-81	12.3	144
284	Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential. *European Journal of Heart Failure*, **2015**, 17, 764-71	12.3	73
283	Geographic differences in heart failure trials. *European Journal of Heart Failure*, **2015**, 17, 893-905	12.3	53
282	Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial. *European Journal of Heart Failure*, **2015**, 17, 1022-31	12.3	40
281	Agents with vasodilator properties in acute heart failure: how to design successful trials. *European Journal of Heart Failure*, **2015**, 17, 652-64	12.3	24
280	Reproducibility in echocardiographic assessment of diastolic function in a population based study (the STANISLAS Cohort study). *PLoS ONE*, **2015**, 10, e0122336	3.7	26
279	Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). *American Heart Journal*, **2015**, 170, 298-305	4.9	32
278	Design considerations for clinical trials of autonomic modulation therapies targeting hypertension and heart failure. *Hypertension*, **2015**, 65, 5-15	8.5	16
277	Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials. *European Journal of Heart Failure*, **2015**, 17, 424-33	12.3	79
276	Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial). *American Journal of Cardiology*, **2015**, 115, 790-6	3	28
275	Emerging cardiovascular indications of mineralocorticoid receptor antagonists. *Trends in Endocrinology and Metabolism*, **2015**, 26, 201-11	8.8	23

274	Population risk prediction models for incident heart failure: a systematic review. *Circulation: Heart Failure*, **2015**, 8, 438-47	7.6	40
273	Neutrophil Gelatinase-Associated Lipocalin, a Novel Mineralocorticoid Biotarget, Mediates Vascular Profibrotic Effects of Mineralocorticoids. *Hypertension*, **2015**, 66, 158-66	8.5	60
272	Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database Initiative. *European Journal of Heart Failure*, **2015**, 17, 1144-51	12.3	63
271	Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial. *European Journal of Heart Failure*, **2015**, 17, 98-108	12.3	23
270	Sleep-disordered Breathing in Heart Failure - Current State of the Art. *Cardiac Failure Review*, **2015**, 1, 16-24	4.2	1
269	Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial. *Archives of Cardiovascular Diseases*, **2014**, 107, 149-57	2.7	7
268	Decongestion in acute heart failure. *European Journal of Heart Failure*, **2014**, 16, 471-82	12.3	90
267	Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). *American Journal of Cardiology*, **2014**, 114, 1713-21	3	35
266	Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). *Circulation: Heart Failure*, **2014**,	7.6	154
265	Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. *European Heart Journal*, **2014**, 35, 2295-302	9.5	100
264	Charting a roadmap for heart failure biomarker studies. *JACC: Heart Failure*, **2014**, 2, 477-88	7.9	54
263	Current challenges for clinical trials of cardiovascular medical devices. *International Journal of Cardiology*, **2014**, 175, 30-7	3.2	31
262	Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. *JACC: Heart Failure*, **2014**, 2, 260-8	7.9	79
261	Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. *Heart Failure Reviews*, **2014**, 19, 135-52	5	39
260	Telemedicine: what framework, what levels of proof, implementation rules. *Therapie*, **2014**, 69, 339-54	3.8	2
259	Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome. *Thrombosis and Haemostasis*, **2014**, 111, 1141-52	7	23
258	Simultaneous characterization of metabolic, cardiac, vascular and renal phenotypes of lean and obese SHHF rats. *PLoS ONE*, **2014**, 9, e96452	3.7	11
257	Effect of eplerenone in percutaneous coronary intervention-treated post-myocardial infarction patients with left ventricular systolic dysfunction: a subanalysis of the EPHESUS trial. *European Journal of Heart Failure*, **2014**, 16, 685-91	12.3	9

256	Opposite predictive value of pulse pressure and aortic pulse wave velocity on heart failure with reduced left ventricular ejection fraction: insights from an Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) substudy. *Hypertension*, **2014**, 63, 105-11	8.5	61
255	Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms. *Heart*, **2014**, 100, 1681-7	5.1	21
254	Incident heart failure in relation to vascular disease: insights from the Health, Aging, and Body Composition Study. *European Journal of Heart Failure*, **2014**, 16, 526-34	12.3	15
253	Trials of implantable monitoring devices in heart failure: which design is optimal?. *Nature Reviews Cardiology*, **2014**, 11, 576-85	14.8	27
252	Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. *European Journal of Heart Failure*, **2014**, 16, 76-85	12.3	56
251	High prevalence of iron deficiency in patients with acute decompensated heart failure. *European Journal of Heart Failure*, **2014**, 16, 984-91	12.3	77
250	Rationale and study design of the NEuroCardiac TherApy foR Heart Failure Study: NECTAR-HF. *European Journal of Heart Failure*, **2014**, 16, 692-9	12.3	42
249	Noncardiac comorbidities in heart´failure´with reduced versus preserved´ejection fraction. *Journal of the American College of Cardiology*, **2014**, 64, 2281-93	15.1	313
248	Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure. *European Journal of Heart Failure*, **2014**, 16, 143-50	12.3	19
247	2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. *Blood Pressure*, **2014**, 23, 3-16	1.7	474
246	The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27 610 patients. *European Journal of Heart Failure*, **2014**, 16, 289-99	12.3	15
245	Features of cardiac remodeling, associated with blood pressure and fibrosis biomarkers, are frequent in subjects with abdominal obesity. *Hypertension*, **2014**, 63, 740-6	8.5	36
244	Home blood pressure monitoring: a few minutes of rest before measurement may not be appropriate. *American Journal of Hypertension*, **2014**, 27, 932-8	2.3	4
243	Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. *Circulation: Heart Failure*, **2014**, 7, 573-9	7.6	112
242	Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data. *Journal of the American College of Cardiology*, **2014**, 63, 853-71	15.1	80
241	Heart RomicsPin AGEing (HOMAGE): design, research objectives and characteristics of the common database. *Journal of Biomedical Research*, **2014**, 28, 349-59	1.5	16
240	Loop diuretics and ultrafiltration in heart failure. *Expert Opinion on Pharmacotherapy*, **2013**, 14, 1641-8	4	5
239	Peripheral artery disease and outcomes after myocardial infarction: an individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT. *International Journal of Cardiology*, **2013**, 168, 1094-101	3.2	34

238	Effectiveness of a multidimensional home nurse led heart failure disease management program--a French nationwide time-series comparison. *International Journal of Cardiology*, **2013**, 168, 3652-8	3.2	19
237	Alogliptin after acute coronary syndrome in patients with type 2 diabetes. *New England Journal of Medicine*, **2013**, 369, 1327-35	59.2	1858
236	Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). *Journal of the American College of Cardiology*, **2013**, 62, 1585-93	15.1	168
235	Learning from recent trials and shaping the future of acute heart failure trials. *American Heart Journal*, **2013**, 166, 629-35	4.9	21
234	Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial. *European Journal of Heart Failure*, **2013**, 15, 61-8	12.3	15
233	The past, present and future of renin-angiotensin aldosterone system inhibition. *International Journal of Cardiology*, **2013**, 167, 1677-87	3.2	82
232	Galectin-3 mediates aldosterone-induced vascular fibrosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2013**, 33, 67-75	9.4	255
231	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). *Revista Portuguesa De Cardiologia (English Edition)*, **2013**, 32, 553-554	0	2
230	Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. *International Journal of Cardiology*, **2013**, 167, 1772-82	3.2	53
229	Clustering of 37 circulating biomarkers by exploratory factor analysis in patients following complicated acute myocardial infarction. *International Journal of Cardiology*, **2013**, 166, 729-35	3.2	27
228	The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. *JACC: Heart Failure*, **2013**, 1, 488-96	7.9	49
227	Clinical usefulness of an assay for measurement of circulating N-terminal pro-B-type natriuretic peptide concentration in dogs and cats with heart disease. *Journal of the American Veterinary Medical Association*, **2013**, 243, 71-82	1	36
226	Continuous positive airway pressure (CPAP) may not reduce short-term mortality in cardiogenic pulmonary edema: a propensity-based analysis. *Journal of Cardiac Failure*, **2013**, 19, 108-16	3.3	7
225	Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. *Journal of the American College of Cardiology*, **2013**, 61, 571-9	15.1	47
224	Relationship between catalase haplotype and arterial aging. *Atherosclerosis*, **2013**, 227, 100-5	3.1	11
223	Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial). *American Journal of Cardiology*, **2013**, 112, 1763-9	3	6
222	Anticoagulation in heart failure: current status and future direction. *Heart Failure Reviews*, **2013**, 18, 797-813	5	22
221	Association between resting heart rate, chronotropic index, and long-term outcomes in patients with heart failure receiving β-blocker therapy: data from the HF-ACTION trial. *European Heart Journal*, **2013**, 34, 2271-80	9.5	44

220	Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. *Journal of Cardiac Failure*, **2013**, 19, 390-7	3.3	100
219	Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. *JAMA - Journal of the American Medical Association*, **2013**, 309, 1125-35	27.4	248
218	2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *European Heart Journal*, **2013**, 34, 2159-219	9.5	3400
217	Statin therapy and clinical outcomes in myocardial infarction patients complicated by acute heart failure: insights from the EPHESUS trial. *European Journal of Heart Failure*, **2013**, 15, 221-7	12.3	9
216	Prognostic value of serum PIIINP, MMP1 and TIMP1 levels in hypertensive patients: a community-based prospective cohort study. *Fundamental and Clinical Pharmacology*, **2013**, 27, 572-80	3.1	16
215	Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. *European Heart Journal*, **2013**, 34, 835-43	9.5	276
214	International differences in treatment effect: do they really exist and why?. *European Heart Journal*, **2013**, 34, 1846-52	9.5	37
213	Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. *European Heart Journal*, **2013**, 34, 3117-27	9.5	47
212	Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. *European Heart Journal*, **2013**, 34, 2453-63	9.5	282
211	Determinants of cardiovascular risk in haemodialysis patients: post hoc analyses of the AURORA study. *American Journal of Nephrology*, **2013**, 37, 144-51	4.6	22
210	Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study. *Circulation: Heart Failure*, **2013**, 6, 711-8	7.6	26
209	Race influences the safety and efficacy of spironolactone in severe heart failure. *Circulation: Heart Failure*, **2013**, 6, 970-6	7.6	27
208	Extracellular matrix turnover biomarkers predict long-term left ventricular remodeling after myocardial infarction: insights from the REVE-2 study. *Circulation: Heart Failure*, **2013**, 6, 1199-205	7.6	27
207	Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes. *Circulation: Heart Failure*, **2013**, 6, 1172-9	7.6	95
206	Visit-to-visit blood pressure variability and risk for progression of cardiovascular and renal diseases. *Current Opinion in Nephrology and Hypertension*, **2013**, 22, 59-64	3.5	23
205	The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. *European Heart Journal*, **2013**, 34, 2823-9	9.5	61
204	Absence of cardiotrophin 1 is associated with decreased age-dependent arterial stiffness and increased longevity in mice. *Hypertension*, **2013**, 61, 120-9	8.5	35
203	Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial. *European Journal of Heart Failure*, **2013**, 15, 1228-35	12.3	46

202	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. *European Journal of Heart Failure*, **2013**, 15, 1173-84	12.3	388
201	Rationale and design of the SERVE-HF study: treatment of sleep-disordered breathing with predominant central sleep apnoea with adaptive servo-ventilation in patients with chronic heart failure. *European Journal of Heart Failure*, **2013**, 15, 937-43	12.3	89
200	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. *European Journal of Heart Failure*, **2013**, 15, 1082-94	12.3	143
199	Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. *European Journal of Heart Failure*, **2013**, 15, 194-202	12.3	126
198	EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). *European Journal of Heart Failure*, **2013**, 15, 808-17	12.3	462
197	Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial. *European Journal of Heart Failure*, **2013**, 15, 1382-9	12.3	18
196	Gene expression profile of blood cells for the prediction of delayed cerebral ischemia after intracranial aneurysm rupture: a pilot study in humans. *Cerebrovascular Diseases*, **2013**, 36, 236-42	3.2	8
195	Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. *Circulation: Heart Failure*, **2013**, 6, 47-52	7.6	56
194	A role for soluble ST2 in vascular remodeling associated with obesity in rats. *PLoS ONE*, **2013**, 8, e79176	3.7	29
193	The effectiveness of inodilators in reducing short term mortality among patient with severe cardiogenic shock: a propensity-based analysis. *PLoS ONE*, **2013**, 8, e71659	3.7	33
192	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). *Atherosclerosis*, **2012**, 223, 1-68	3.1	286
191	Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). *European Journal of Heart Failure*, **2012**, 14, 909-15	12.3	48
190	Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. *European Journal of Heart Failure*, **2012**, 14, 1401-9	12.3	21
189	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). *European Heart Journal*, **2012**, 33, 1635-701	9.5	2797
188	Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. *European Journal of Heart Failure*, **2012**, 14, 74-81	12.3	167
187	ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *European Journal of Heart Failure*, **2012**, 14, 803-69	12.3	1892
186	Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques. *Fundamental and Clinical Pharmacology*, **2012**, 26, 163-74	3.1	24
185	Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. *Circulation*, **2012**, 126, 2317-23	16.7	73

184	Hypo- and hyperglycemia predict outcome in patients with left ventricular dysfunction after acute myocardial infarction: data from EPHESUS. *Journal of Cardiac Failure*, **2012**, 18, 439-45	3.3	27
183	The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial. *Journal of Cardiac Failure*, **2012**, 18, 515-23	3.3	51
182	Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. *Circulation: Heart Failure*, **2012**, 5, 750-8	7.6	62
181	Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). *Journal of the American College of Cardiology*, **2012**, 60, 2082-9	15.1	165
180	Implications of geographical variation on clinical outcomes of cardiovascular trials. *American Heart Journal*, **2012**, 164, 303-12	4.9	31
179	Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. *Journal of the American College of Cardiology*, **2012**, 59, 1598-603	15.1	189
178	Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). *American Journal of Cardiology*, **2012**, 110, 1657-62	3	9
177	Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial). *American Journal of Cardiology*, **2012**, 110, 1803-8	3	6
176	Can we prevent or treat renal dysfunction in chronic heart failure?. *Heart Failure Reviews*, **2012**, 17, 283-90	5	7
175	A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90´days: analysis from the EVEREST trial. *Heart Failure Reviews*, **2012**, 17, 485-509	5	79
174	Predicting maximal HR in heart failure patients on β-blockade therapy. *Medicine and Science in Sports and Exercise*, **2012**, 44, 371-6	1.2	29
173	Eplerenone: is it time to add this drug to current heart failure therapy?. *Therapeutic Advances in Chronic Disease*, **2012**, 3, 5-9	4.9	6
172	Neutrophil gelatinase-associated lipocalin is a novel mineralocorticoid target in the cardiovascular system. *Hypertension*, **2012**, 59, 966-72	8.5	63
171	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the	9.5	3691
170	Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. *Circulation*, **2012**, 125, 271-9	16.7	97
169	Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. *Circulation: Heart Failure*, **2012**, 5, 72-8	7.6	173
168	Visit-to-visit blood pressure variability is a strong predictor of cardiovascular events in hemodialysis: insights from FOSIDIAL. *Hypertension*, **2012**, 60, 339-46	8.5	80
167	Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. *European Journal of Heart Failure* , **2012**, 14, 668-75	12.3	60

166	Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. *European Journal of Heart Failure*, **2012**, 14, 302-11	12.3	126
165	Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction: the HF-ACTION predictive risk score model. *Circulation: Heart Failure*, **2012**, 5, 63-71	7.6	153
164	Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. *European Heart Journal*, **2012**, 33, 2782-95	9.5	121
163	When to stop a clinical trial early for benefit: lessons learned and future approaches. *Circulation: Heart Failure*, **2012**, 5, 294-302	7.6	18
162	Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction. *Hypertension*, **2012**, 60, 563-73	8.5	52
161	Risk-guided therapy: a first step to personalized medicine. *European Journal of Preventive Cardiology*, **2012**, 19, 5-6	3.9	6
160	Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?. *European Heart Journal*, **2012**, 33, 1049-57	9.5	17
159	Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. *Journal of Cardiovascular Medicine*, **2012**, 13, 415-22	1.9	26
158	Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. *Journal of the American College of Cardiology*, **2011**, 58, 1958-66	15.1	96
157	Eplerenone in patients with systolic heart failure and mild symptoms. *New England Journal of Medicine*, **2011**, 364, 11-21	59.2	1890
156	Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. *American Heart Journal*, **2011**, 161, 1067-72	4.9	29
155	The prognostic value of circulating markers of collagen turnover after acute myocardial infarction. *International Journal of Cardiology*, **2011**, 150, 277-82	3.2	32
154	Surrogate endpoints in randomized cardiovascular clinical trials. *Fundamental and Clinical Pharmacology*, **2011**, 25, 411-3	3.1	12
153	Evaluation of the functional status questionnaire in heart failure: a sub-study of the second cardiac insufficiency bisoprolol survival study (CIBIS-II). *Cardiovascular Drugs and Therapy*, **2011**, 25, 77-85	3.9	8
152	Clinical trials in acute heart failure: simpler solutions to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round-table think tank on acute heart failure, 12 May 2009. *European Journal of Heart Failure*, **2011**, 13, 1253-60	12.3	27
151	Association between markers of collagen turnover, arterial stiffness and left ventricular hypertrophy in chronic kidney disease (CKD): the Renal Research Institute (RRI)-CKD study. *Nephrology Dialysis Transplantation*, **2011**, 26, 2891-8	4.3	23
150	Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. *European Heart Journal*, **2011**, 32, 820-8	9.5	259
149	Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. *European Heart Journal*, **2011**, 32, 2563-72	9.5	99

148	Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). *European Journal of Heart Failure*, **2011**, 13, 100-6	12.3	60
147	Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. *European Journal of Heart Failure*, **2011**, 13, 1-10	12.3	295
146	Rosuvastatin in diabetic hemodialysis patients. *Journal of the American Society of Nephrology: JASN*, **2011**, 22, 1335-41	12.7	80
145	Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. *Circulation: Cardiovascular Quality and Outcomes*, **2011**, 4, 389-98	5.8	86
144	Association study of gene polymorphisms involved in vascular alterations in elderly hypertensives with subjective memory complaints. *Dementia and Geriatric Cognitive Disorders*, **2010**, 30, 440-8	2.6	10
143	EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). *European Journal of Heart Failure*, **2010**, 12, 1076-84	12.3	258
142	Critical elements of clinical follow-up after hospital discharge for heart failure: insights from the EVEREST trial. *European Journal of Heart Failure*, **2010**, 12, 367-74	12.3	56
141	Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. *European Journal of Heart Failure*, **2010**, 12, 607-16	12.3	50
140	Of fads, fashion, surrogate endpoints and dual RAS blockade. *European Heart Journal*, **2010**, 31, 2205-8	9.5	29
139	Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. *European Journal of Heart Failure*, **2010**, 12, 423-33	12.3	436
138	Left bundle branch block and mortality in patients with acute heart failure syndrome: a substudy of the EFICA cohort. *European Journal of Heart Failure*, **2010**, 12, 156-63	12.3	26
137	Transatlantic similarities and differences in major natural history endpoints of heart failure after acute myocardial infarction: a propensity-matched study of the EPHESUS trial. *International Journal of Cardiology*, **2010**, 143, 309-16	3.2	15
136	Maximizing scientific knowledge from randomized clinical trials. *American Heart Journal*, **2010**, 159, 937-43	4.9	10
135	Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). *European Journal of Heart Failure*, **2010**, 12, 617-22	12.3	57
134	Effect of two oral doses of 17beta-estradiol associated with dydrogesterone on thrombin generation in healthy menopausal women: a randomized double-blind placebo-controlled study. *Fundamental and Clinical Pharmacology*, **2010**, 24, 239-45	3.1	1
133	Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. *Circulation: Heart Failure*, **2010**, 3, 314-25	7.6	120
132	Implantable cardioverter-defibrillators in patients hospitalized for heart failure with chronically reduced left ventricular ejection fraction. *American Journal of Therapeutics*, **2010**, 17, e78-87	1	16
131	Extracellular matrix fibrotic markers in heart failure. *Heart Failure Reviews*, **2010**, 15, 319-29	5	70

130	Heart Failure Pilot protocol. *European Heart Journal*, **2010**, 31, 2184-6	9.5	1
129	Cardiovascular disease in patients with renal disease: the role of statins. *Current Medical Research and Opinion*, **2009**, 25, 271-85	2.5	29
128	Vascular structure and function is correlated to cognitive performance and white matter hyperintensities in older hypertensive patients with subjective memory complaints. *Stroke*, **2009**, 40, 1229-36	6.7	197
127	Pulse wave velocity assessment by external noninvasive devices and phase-contrast magnetic resonance imaging in the obese. *Hypertension*, **2009**, 54, 421-6	8.5	81
126	Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. *European Journal of Heart Failure*, **2009**, 11, 119-29	12.3	248
125	Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. *European Heart Journal*, **2009**, 30, 1666-73	9.5	55
124	Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. *Circulation*, **2009**, 119, 2471-9	16.7	195
123	Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. *JAMA - Journal of the American Medical Association*, **2009**, 301, 1439-50	27.4	1259
122	Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial. *American Journal of Cardiology*, **2009**, 103, 82-7	3	64
121	Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. *European Journal of Heart Failure*, **2009**, 11, 1099-105	12.3	63
120	Unconventional end points in cardiovascular clinical trials: should we be moving away from morbidity and mortality?. *Journal of Cardiac Failure*, **2009**, 15, 199-205	3.3	23
119	Low serum magnesium and cardiovascular mortality in chronic heart failure: a propensity-matched study. *International Journal of Cardiology*, **2009**, 136, 270-7	3.2	53
118	N-terminal pro-brain natriuretic peptide and exercise capacity in chronic heart failure: data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study. *American Heart Journal*, **2009**, 158, S37-44	4.9	22
117	Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling. *JACC: Cardiovascular Imaging*, **2009**, 2, 187-98	8.4	48
116	Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. *New England Journal of Medicine*, **2009**, 360, 1395-407	59.2	1414
115	Biomarkers of extracellular matrix turnover. *Heart Failure Clinics*, **2009**, 5, 589-99	3.3	5
114	Effects of tolvaptan on dyspnoea relief from the EVEREST trials. *European Heart Journal*, **2009**, 30, 2233-40	9.9	58
113	C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor alpha, on human monocytes. *Thrombosis and Haemostasis*, **2008**, 99, 558-69	7	46

112	Sympathetic-leptin relationship in obesity: effect of weight loss. *Metabolism: Clinical and Experimental*, **2008**, 57, 555-62	12.7	29
111	Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. *Journal of the American College of Cardiology*, **2008**, 52, 1640-8	15.1	141
110	Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction. *Journal of the American College of Cardiology*, **2008**, 52, 2017-28	15.1	119
109	A propensity matched study of the association of education and outcomes in chronic heart failure. *International Journal of Cardiology*, **2008**, 129, 93-9	3.2	34
108	Incident heart failure hospitalization and subsequent mortality in chronic heart failure: a propensity-matched study. *Journal of Cardiac Failure*, **2008**, 14, 211-8	3.3	117
107	Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. *Journal of Cardiac Failure*, **2008**, 14, 467-74	3.3	69
106	C-reactive protein (CRP) increases VEGF-A expression in monocytic cells via a PI3-kinase and ERK 1/2 signaling dependent pathway. *Atherosclerosis*, **2008**, 200, 286-93	3.1	33
105	Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. *JAMA - Journal of the American Medical Association*, **2008**, 299, 2656-66	27.4	128
104	Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. *European Heart Journal*, **2008**, 29, 748-56	9.5	76
103	Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. *European Heart Journal*, **2008**, 29, 1739-52	9.5	70
102	Overview of emerging pharmacologic agents for acute heart failure syndromes. *European Journal of Heart Failure*, **2008**, 10, 201-13	12.3	36
101	Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition. *European Heart Journal*, **2008**, 29, 413-21	9.5	35
100	Successful treatment of heart failure with devices requires collaboration. *European Journal of Heart Failure*, **2008**, 10, 1229-35	12.3	21
99	History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. *Hypertension*, **2008**, 52, 271-8	8.5	21
98	State of the art: using natriuretic peptide levels in clinical practice. *European Journal of Heart Failure*, **2008**, 10, 824-39	12.3	529
97	Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. *Critical Care Medicine*, **2008**, 36, S129-39	1.4	188
96	Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies. *Fundamental and Clinical Pharmacology*, **2007**, 21, 181-90	3.1	25
95	Haemorheological disturbances in hypertensive type 2 diabetic patients--influence of antihypertensive therapy. *Fundamental and Clinical Pharmacology*, **2007**, 21, 387-96	3.1	13

94	Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. *American Journal of Cardiology*, **2007**, 100, 222-6	3	27
93	An introduction to acute heart failure syndromes: definition and classification. *Heart Failure Reviews*, **2007**, 12, 87-90	5	51
92	Epidemiology of acute heart failure syndromes. *Heart Failure Reviews*, **2007**, 12, 91-5	5	96
91	Residual stress ischaemia is associated with blood markers of myocardial structural remodelling. *European Journal of Heart Failure*, **2007**, 9, 370-6	12.3	10
90	Ejection fraction and blood pressure are important and interactive predictors of 4-week mortality in severe acute heart failure. *European Journal of Heart Failure*, **2007**, 9, 935-41	12.3	26
89	Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction. *Europace*, **2007**, 9, 724-9	3.9	62
88	A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. *European Heart Journal*, **2007**, 28, 1334-43	9.5	146
87	Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. *European Heart Journal*, **2007**, 28, 1904-9	9.5	18
86	Left bundle branch block as a risk factor for progression to heart failure. *European Journal of Heart Failure*, **2007**, 9, 7-14	12.3	112
85	Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. *JAMA - Journal of the American Medical Association*, **2007**, 297, 1319-31	27.4	1118
84	Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. *JAMA - Journal of the American Medical Association*, **2007**, 297, 1332-43	27.4	625
83	Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. *Kidney and Blood Pressure Research*, **2007**, 30, 314-22	3.1	45
82	Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in dialysis study. *Nephrology Dialysis Transplantation*, **2007**, 22, 3573-9	4.3	35
81	Amlodipine added to quinapril vs quinapril alone for the treatment of hypertension in diabetes: the Amlodipine in Diabetes (ANDI) trial. *Journal of Clinical Hypertension*, **2007**, 9, 120-7	2.3	10
80	Globalization of cardiovascular clinical research: the balance between meeting medical needs and maintaining scientific standards. *American Heart Journal*, **2007**, 154, 232-8	4.9	32
79	Early changes in serum markers of cardiac extra-cellular matrix turnover in patients with uncomplicated hypertension and type II diabetes. *European Journal of Heart Failure*, **2006**, 8, 147-53	12.3	55
78	Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. *European Journal of Heart Failure*, **2006**, 8, 591-8	12.3	92
77	Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction . *European Journal of Heart Failure*, **2006**, 8, 295-301	12.3	30

76	Benefits, challenges, and registerability of the polypill. *European Heart Journal*, **2006**, 27, 1651-6	9.5	79
75	Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study. *European Journal of Heart Failure*, **2006**, 8, 697-705	12.3	234
74	The challenge of acute decompensated heart failure. *Heart Failure Reviews*, **2006**, 11, 135-9	5	24
73	Initial infarct size predicts subsequent cardiac remodeling in the rat infarct model: an in vivo serial pinhole gated SPECT study. *Journal of Nuclear Medicine*, **2006**, 47, 337-44	8.9	17
72	Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials. *Journal of Cardiovascular Pharmacology*, **2006**, 47, 469-75	3.1	19
71	Public awareness of heart failure in Europe: first results from SHAPE. *European Heart Journal*, **2005**, 26, 2413-21	9.5	85
70	Retinoic acid amplifies the host immune response to LPS through increased T lymphocytes number and LPS binding protein expression. *Molecular and Cellular Endocrinology*, **2005**, 245, 67-76	4.4	27
69	Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). *Journal of Cardiac Failure*, **2005**, 11, 260-9	3.3	154
68	Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. *Journal of the American College of Cardiology*, **2005**, 46, 425-31	15.1	284
67	Impaired response of cardiac autonomic nervous system to glucose load in severe obesity. *Metabolism: Clinical and Experimental*, **2005**, 54, 966-74	12.7	11
66	Changes in first-pass interstitial kinetics of DTPA in myocardium submitted to low-flow ischemia. *Investigative Radiology*, **2005**, 40, 766-72	10.1	4
65	Anaphylactic shock: a form of distributive shock without inhibition of oxygen consumption. *Anesthesiology*, **2005**, 103, 40-9	4.3	49
64	High-resolution simultaneous imaging of SPECT, PET, and MRI tracers on histologic sections of myocardial infarction. *Journal of Nuclear Cardiology*, **2005**, 12, 229-30	2.1	12
63	Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure. *Heart Failure Reviews*, **2005**, 10, 71-8	5	60
62	Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. *Blood Pressure*, **2005**, 14, 196-209	1.7	59
61	Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). *Circulation*, **2005**, 112, 3391-9	16.7	93
60	Acute heart failure syndromes: current state and framework for future research. *Circulation*, **2005**, 112, 3958-68	16.7	583
59	Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). *Circulation*, **2004**, 109, 1594-602	16.7	856

58	Rationale, design and methods of the CASHMERE study. *Fundamental and Clinical Pharmacology*, **2004**, 18, 131-8	3.1	14
57	Differential time effect profiles of amlodipine, as compared to valsartan, revealed by ambulatory blood pressure monitoring, self blood pressure measurements and dose omission protocol. *Fundamental and Clinical Pharmacology*, **2004**, 18, 483-91	3.1	8
56	Increasing awareness and perception of heart failure in Europe and improving care--rationale and design of the SHAPE Study. *Cardiovascular Drugs and Therapy*, **2004**, 18, 153-9	3.9	13
55	Efficacité comparée des trois stratégies antihypertensives recommandées en Europe. *American Journal of Cardiovascular Drugs*, **2004**, 4, 13-14	4	
54	Exercise release of cardiac natriuretic peptides is markedly enhanced when patients with coronary artery disease are treated medically by beta-blockers. *Journal of the American College of Cardiology*, **2004**, 43, 353-9	15.1	37
53	Low-flow ischaemia has no deleterious effect on the steady-state kinetics of 201Tl and 99mTc sestamibi within myocardial tissue. *Nuclear Medicine Communications*, **2004**, 25, 475-8	1.6	2
52	The Results of Major Clinical Trials. *Therapie*, **2004**, 59, 323-328	3.8	
51	Genetics of intima-media thickness. *Current Opinion in Lipidology*, **2003**, 14, 191-200	4.4	22
50	Residual exercise SPECT ischemia on treatment is a main determinant of outcome in patients with coronary artery disease treated medically at long-term with beta-blockers. *Journal of Nuclear Cardiology*, **2003**, 10, 361-8	2.1	13
49	Improving ACE inhibitor use in patients hospitalized with systolic heart failure: a cluster randomized controlled trial of clinical practice guideline development and use. *Journal of Evaluation in Clinical Practice*, **2003**, 9, 373-82	2.5	10
48	Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *New England Journal of Medicine*, **2003**, 348, 1309-21	59.2	3668
47	Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. *Circulation*, **2003**, 108, 1831-8	16.7	518
46	FOSIDIAL: a randomised placebo controlled trial of the effects of fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. Study design and patients' baseline characteristics. *Fundamental and Clinical Pharmacology*, **2002**, 16, 353-60	3.1	14
45	Time-effect profile of antihypertensive agents assessed with trough/peak ratio, smoothness index and dose omission: an ambulatory blood pressure monitoring study with trandolapril vs. quinapril. *Fundamental and Clinical Pharmacology*, **2002**, 16, 545-54	3.1	3
44	Angiotensin-Converting Enzyme Inhibitors in Congestive Heart Failure: Practice versus Guidelines. *Journal of Pharmacy Technology*, **2002**, 18, 229-240	0.6	1
43	Self-rating of quality of life provides additional prognostic information in heart failure. Insights into the EPICAL study. *European Journal of Heart Failure*, **2002**, 4, 337-43	12.3	111
42	Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. *American Heart Journal*, **2002**, 144, 508-15	4.9	60
41	Impaired autonomic control of heart rate and blood pressure in obesity: role of age and of insulin-resistance. *Clinical Autonomic Research*, **2001**, 11, 79-86	4.3	32

40	Contrasting effects of verapamil and amlodipine on cardiovascular stress responses in hypertension. *British Journal of Clinical Pharmacology*, **2001**, 52, 687-92	3.8	5
39	The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. *Cardiovascular Drugs and Therapy*, **2001**, 15, 79-87	3.9	248
38	Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. *Hypertension*, **2001**, 38, 1227-32	8.5	106
37	Lipopolysaccharide-induced increase of prostaglandin E(2) is mediated by inducible nitric oxide synthase activation of the constitutive cyclooxygenase and induction of membrane-associated prostaglandin E synthase. *Journal of Immunology*, **2001**, 167, 3962-71	5.3	51
36	Retinoic acid attenuates inducible nitric oxide synthase (NOS2) activation in cultured rat cardiac myocytes and microvascular endothelial cells. *Journal of Molecular and Cellular Cardiology*, **2001**, 33, 933-45	5.8	24
35	Hemodynamics as surrogate end points for survival in advanced heart failure: an analysis from FIRST. *American Heart Journal*, **2001**, 141, 908-14	4.9	26
34	The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study. *American Journal of Hypertension*, **2001**, 14, 1083-9	2.3	40
33	Antihypertensive drugs. *Side Effects of Drugs Annual*, **2001**, 24, 233-245	0.2	
32	Retinoic acid and lipopolysaccharide act synergistically to increase prostanoid concentrations in rats in vivo. *Journal of Nutrition*, **2001**, 131, 2628-35	4.1	13
31	Preserving Target-organ Function with Candesartan Cilexetil in Patients with Hypertension. *Blood Pressure*, **2000**, 9, 36-39	1.7	7
30	Differential clinical prognostic classifications in dilated and ischemic advanced heart failure: the EPICAL study. *American Heart Journal*, **2000**, 139, 895-904	4.9	61
29	Relationship between E-selectin L/F554 polymorphism and blood pressure in the Stanislas cohort. *Human Genetics*, **2000**, 107, 58-61	6.3	15
28	Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. *Circulation*, **2000**, 102, 2700-6	16.7	750
27	Antihypertensive drugs. *Side Effects of Drugs Annual*, **2000**, 23, 217-224	0.2	
26	Effets des inhibiteurs calciques sur la progression de l??ath??roscl??rose et de l????paisseur intima m??dia. *Drugs*, **2000**, 59, 39-46	12.1	3
25	The potential advantages of a modern antihypertensive therapy in the elderly. *Journal of Cardiovascular Pharmacology*, **2000**, 35, S19-23	3.1	10
24	The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *New England Journal of Medicine*, **1999**, 341, 709-17	59.2	6637
23	Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Epidémiologie de l'Insuffisance Cardiaque Avancée en Lorraine. *Journal of the American College of Cardiology*, **1999**, 33, 734-42	15.1	226

22	Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). *American Heart Journal*, **1999**, 138, 78-86	4.9	395
21	Antihypertensive drugs. *Side Effects of Drugs Annual*, **1999**, 22, 224-232	0.2	
20	Beta-blocker therapy in advanced heart failure: clinical characteristics and long-term outcomes. *European Journal of Heart Failure*, **1999**, 1, 81-8	12.3	14
19	Over 20 yearsPexperience of beta-blockade in heart failure. *Progress in Cardiovascular Diseases*, **1998**, 41, 31-7	8.5	4
18	Differential effects of fosinopril and enalapril in patients with mild to moderate chronic heart failure. Fosinopril in Heart Failure Study Investigators. *American Heart Journal*, **1998**, 136, 672-80	4.9	13
17	Clinical definition and epidemiology of advanced heart failure. *American Heart Journal*, **1998**, 135, S204-15	4.9	113
16	Apolipoprotein E4, lipoprotein lipase C447 and angiotensin-I converting enzyme deletion alleles were not associated with increased wall thickness of carotid and femoral arteries in healthy subjects from the Stanislas cohort. *Atherosclerosis*, **1998**, 140, 89-95	3.1	50
15	Antihypertensive drugs. *Side Effects of Drugs Annual*, **1997**, 20, 194-199	0.2	
14	A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). *American Heart Journal*, **1997**, 134, 44-54	4.9	543
13	Effects of blood pressure control on radial artery diameter and compliance in hypertensive patients. *American Journal of Hypertension*, **1997**, 10, 269-74	2.3	13
12	Frequencies of five genetic polymorphisms in coronarographed patients and effects on lipid levels in a supposedly healthy population. *Clinical Genetics*, **1996**, 50, 339-47	4	18
11	Physical deconditioning may be a mechanism for the skeletal muscle energy phosphate metabolism abnormalities in chronic heart failure. *American Heart Journal*, **1996**, 131, 560-6	4.9	49
10	Investigations of the peripheral vascular mechanisms implicated in congestive heart failure by the non-invasive evaluation of radial artery compliance and reactivity. *International Journal of Cardiology*, **1996**, 56, 149-58	3.2	16
9	Effect of improved disease management strategies on hospital length of stay in the treatment of congestive heart failure. *Clinical Therapeutics*, **1996**, 18, 726-46; discussion 702	3.5	19
8	Plasma levels of atrial natriuretic peptide and of other vasoconstricting hormones in patients with chronic heart failure: relationship to exercise capacity. *International Journal of Cardiology*, **1996**, 57, 135-42	3.2	5
7	Duration of action of angiotensin converting enzyme inhibitors. *American Journal of Hypertension*, **1995**, 8, 75S-81S	2.3	12
6	Antihypertensive drugs. *Side Effects of Drugs Annual*, **1995**, 19, 209-217	0.2	
5	Contribution of specific skeletal muscle metabolic abnormalities to limitation of exercise capacity in patients with chronic heart failure: a phosphorus 31 nuclear magnetic resonance study. *American Heart Journal*, **1994**, 128, 781-92	4.9	32

4	Antihypertensive drugs. *Side Effects of Drugs Annual*, **1994**, 18, 222-227	0.2	
3	Effect of diltiazem on myocardial infarct size estimated by enzyme release, serial thallium-201 single-photon emission computed tomography and radionuclide angiography. *American Journal of Cardiology*, **1988**, 61, 1172-7	3	21
2	Clinical research in Africa And Middle East: Roadmap for reform and harmonisation of the regulatory framework and sustainable capacity development. *Journal of Global Health Reports*,3,	1.1	1
1	Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER -like endpoint definitions. *European Journal of Heart Failure*,	12.3	4